NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Ideaya Biosciences, Inc. IDYA
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$218.7M
▲ 3024.4% vs FY2024
EPS · FY25
$-1.28
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-10.9%
Net margin · FY25
-52.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 218.7M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 52 cents on every revenue dollar this year.
Per share
USD -1.28
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-10.9%
Return on equity, FY2025
ROE
Operating margin-72.8%
Net margin-52.0%
Return on assets-10.2%
Each USD of equity lost 11 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+62.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+62.5%
+62.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years+197.2%
Change, 10 years—
The share count grew 197% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 1.0B
CashUSD 112.8M
Current ratio11.34×
Equity funds 92% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.2
0.0
0.0
0.1
0.0
0.0
0.0
·
·
Operating income $B
−0.2
−0.3
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.1
−0.3
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.28
−3.36
−1.96
−1.42
−1.41
−1.40
−3.36
−35.92
−17.06
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−10.9
−32.7
−23.3
−18.0
−19.9
−23.1
−163.2
·
·
Shares out B
0.09
0.09
0.07
0.05
0.04
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed